EC
BIO icon

Elequin Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Elequin Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.7K Buy
+217
New +$61.5K ﹤0.01% 294

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Elequin Capital's BIO Position: Q2 2026 in Review

Elequin Capital opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 217 shares worth $63.7K. The stake represents ﹤0.01% of the portfolio and ranks #294 among its holdings.

397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Elequin Capital held 217 shares of Bio-Rad Laboratories Class A worth $63.7K as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new Elequin Capital position in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #294 holding.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.